Auditable Data Transformation in Clinical Trials: Ensuring Regulatory Consistency in R-Generated XPT Files

Abstract

Clinical trials increasingly rely on R for data transformation and the generation of XPT files, the transport format mandated by regulatory agencies such as the U.S. Food and Drug Administration for electronic submissions. While R offers flexibility and open-source accessibility, its default output does not always conform to the stringent metadata and structural requirements imposed by the Clinical Data Interchange Standards Consortium (CDISC) Implementation Guides. Inconsistencies in XPT file attributes, such as variable labels, length definitions, and date-time encodings, can lead to regulatory queries, submission delays, or outright rejection. This paper examines the system-level challenges of ensuring auditability and regulatory consistency when generating XPT files from R. It analyzes architectural trade-offs between reproducibility and compliance, governance mechanisms for maintaining transformation integrity, and the infrastructural sustainability of R-based pipelines within regulated environments. A case illustration of SDTM-to-XPT conversion highlights the interplay between software design, metadata management, and validation protocols. The discussion extends to policy implications, fairness in multi-site data integration, and the robustness of automated audit trails. The paper argues that the gap between R’s flexibility and regulatory rigidity can be bridged through deliberate architecture design, rigorous validation frameworks, and institutional governance that treats data transformation as a first-class compliance artifact. Future directions include standardized extension packages, community-led metadata dictionaries, and integration with continuous validation platforms. The findings contribute to the ongoing discourse on open-source tools in regulated settings and offer guidance for researchers and sponsors seeking to adopt R for clinical submission pipelines.